Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma

Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck Co., Inc., Rahway

Related Keywords

United States ,Chesterford ,Essex ,United Kingdom ,Cambridge ,Cambridgeshire ,British ,Ro Gardner ,Tim Sharpington ,Sanger Institute ,Ip Group ,Chesterford Research Park ,Twitter ,Merck Sharp Dohme ,Merck Co Inc ,Linkedin ,Personalised Bacterial Bank ,Cytotoxict Lymphocyte ,Reference Genome Database ,Culture Collection ,British Patient Capital ,Cambridge Innovation Capital ,Flerie Invest ,Seventure Partners ,Microbiotica ,Nnounces ,Linical ,Trial ,Collaboration ,Valuate ,B097 ,Combination ,Keytruda ,Pembrolizumab ,Hase ,Melanoma ,